Condition
Erythema Chronicum Migrans
Total Trials
5
Recruiting
1
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (4)
P 4 (1)
Trial Status
Completed4
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03337932Not ApplicableRecruitingPrimary
Duration of Doxycycline Treatment in MEM Patients
NCT03153267Not ApplicableCompletedPrimary
Duration of Doxycycline Treatment in EM Patients
NCT03584919Not ApplicableCompletedPrimary
Comparison of Doxycycline and Cefuroxime Axetil in Erythema Migrans
NCT00910715Not ApplicableCompletedPrimary
Duration of Antibiotic Treatment of Erythema Migrans
NCT01368341Phase 4Completed
Comparing 3 Antibiotic Regimes for Erythema Migrans in General Practice
Showing all 5 trials